Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.

“Participating in the program provides grad students with training and an opportunity to share their research, practice their ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Spatial biology first entered the omics scene about a decade ago. Since then, the technology has generated significant buzz ...

Shares in large US and European drugmakers slide, underperforming amid a broad market slump, after President Donald Trump said the US was planning to announce "a major tariff on pharmaceuticals" soon.

Downtown-based biotech firm Onconetix (Nasdaq: ONCO), in an April 3 filing with the Securities and Exchange Commission, ...

President Donald Trump’s exemption of pharmaceuticals from “reciprocal” tariffs limited the declines of biopharma stocks as financial markets tanked late last week—but the specter of future ...

Sapirstein had only held the title for 32 days, assuming the executive chairman role after the company’s latest CEO resigned ...

No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception. This is because biology is by far the most “messy” of hard sciences. Chemistry or physics can deal ...

Of the 30 companies, three saw their stock prices increase, 26 saw their share prices decline, and one company's share price remained virtually flat month over month.